Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
EXPRS2.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-48.01
vs -16.20
Q1.23
N/A
-27.98
vs -15.65
Q2.23
N/A
-25.34
vs -27.90
Q3.23
N/A
-17.60
vs -30.50
Q4.23
N/A
-13.86
vs -48.01
Q1.24
N/A
-10.00
vs -27.98
Q2.24
+103%
0.69
vs -25.34
Q3.24
N/A
-2.82
vs -17.60
Q4.24
N/A
-7.03
vs -13.86
Q1.25
+100%
NA
vs -10.00
Sales Growth
YoY
Current
Estimates
Q4.22
-71%
972K vs 3.4M
Q1.23
+26%
2.6M vs 2M
Q2.23
+54%
1.9M vs 1.2M
Q3.23
+75%
1.5M vs 833K
Q4.23
+14%
1.1M vs 972K
Q1.24
-64%
923K vs 2.6M
Q2.24
-46%
1M vs 1.9M
Q3.24
-68%
459K vs 1.5M
Q4.24
-46%
599K vs 1.1M
Q1.25
+44%
1.3M vs 923K
Return on Equity
QoQ
Q2.23
-30%
-0.30
vs -0.33
Q3.23
-27%
-0.27
vs -0.30
Q4.23
-27%
-0.27
vs -0.27
Q1.24
-25%
-0.25
vs -0.27
Q2.24
+5%
0.05
vs -0.25
Q3.24
-15%
-0.15
vs 0.05
Q4.24
-24%
-0.24
vs -0.15
Q1.25
-22%
-0.22
vs -0.24
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
EXPRS2.ST
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
576%2026-Revenue
-479%2026-EPS
25%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
STO
Unprofitable
EPS improving
Unprofitable
EPS improving
0.35Â ( 1.26%)
Relative Strenght
Volume Buzz
-58%
Earning Acce
No
Dist 52w H.
58%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How EXPRS2.ST compares to sector?